Renal tubular acidosis (RTA) is a disease in which the kidneys fail to excrete acids into the urine as a result the person’s blood remains too acidic. As per DelveInsight’s estimation, in 2017, Renal Tubular Acidosis cases in the United States were reported to be 45,601.
The current standard of care in the Renal Tubular Acidosis therapy market is considered sub-optimally effective with many drawbacks as well. Presently the treatment landscape is led by Advicenne Inc.’s ADV 7103. Apart from the therapeutics front, there are challenges in determining the exact incidence of the disease as many cases often go misdiagnosed or undiagnosed. For more details, visit: Renal Tubular Acidosis Pipeline Therapies